Home / Health / Gujarat Diabetes Drug Sales Surge 25% to Rs 1,196 Crore
Gujarat Diabetes Drug Sales Surge 25% to Rs 1,196 Crore
30 Apr
Summary
- Anti-diabetic drug sales in Gujarat reached Rs 1,196 crore by March 2026.
- Sales saw a 25% increase over two years, with recent quarterly growth at 20%-22%.
- Rising GLP-1 therapies and combination drugs are key drivers of market expansion.
The anti-diabetic drug market in Gujarat has experienced significant growth, with total sales reaching Rs 1,196 crore by March 2026. This figure represents a substantial 25% increase over the past two years, climbing from Rs 962 crore in March 2024. The market's expansion is notably outpacing the national average, with recent quarters showing a sharper year-on-year jump of 20%-22%.
This surge is driven by several factors, including a higher incidence of diabetes, improved detection rates, and a growing preference for advanced treatments. Specifically, the demand for GLP-1 therapies and oral anti-diabetic (OAD) combination drugs has increased. These newer medications, such as those based on semaglutide and tirzepatide, offer greater efficacy in weight reduction and managing comorbidities like hypertension and cardiovascular diseases, compared to older treatments.
